Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Appointment of Chairman and Chief Executive

The board of Cyprotex plc ("Cyprotex" or "the Company") are pleased to announce the appointment of Robert Morrisson Atwater as Chairman and Chief Executive of the Company with immediate effect.

Robert Morrisson Atwater's career to date has spanned 15 years working in the pharmaceutical and biotechnology industries, as well as financial services. Robert joins Cyprotex from San Francisco-based Thalassa Capital Management LLC, an asset management firm which he co-founded which concentrates on bio-pharmaceutical opportunities worldwide in which he will continue to be involved. Prior to Thalassa, Robert worked for five years as a Director of Business Development Europe and Asia for BioChem Pharma, which was subsequently acquired by Shire Pharmaceuticals Group plc. Robert was also responsible for due diligence on biotech companies in Europe. In addition, he developed and maintained banking relationships with the financial community.

Robert has also worked for a number of financial services companies over a 10-year period, including The Nasdaq Stock Market (Europe & Israel), where he was a Managing Director; Istituto Mobiliare Italiano, and Credit Suisse Group. He studied at L�Universite de Neuchatel in Switzerland and is a graduate of the University of Massachusetts at Amherst.

Commenting on the appointment, John Nicholson, Chief Operating Officer of Cyprotex plc, said: "The Board is delighted to welcome Robert to the Company, he brings a wealth of sector knowledge and commercial expertise with him and joins the Company at a pivotal and exciting stage in its development."

Matters for disclosure under paragraph 15 of the AIM Rules with respect to the appointment of Robert Morrisson Atwater as Chief Executive Officer and Director of Cyprotex plc:

Full name: Robert Morrisson Atwater

Age: 40

Current directorships: None

Directorships held within the last 5 years: None

There are no further disclosures required to be made pursuant to paragraph 15 of the AIM Rules for companies.

For further information:

Mr John Nicholson, Chief Operating Officer
Cyprotex PLC

Tel: +44 (0) 1625 505 100

Media enquiries:

Henry Harrison-Topham
Bankside Consultants Limited

Tel: +44 (0) 20 7444 4140

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.